Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZW25 in HER2-overexpressed endometrial cancer and carcinosarcoma
NCT04513665Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2020
- Primary completion
- Mar 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zanidatamab in endometrial cancer (EC), carcinosarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2020; status: completed.
02
Drugs
zanidatamab
03
Conditions
endometrial cancer (EC)carcinosarcoma
Beyond the preview
Go deeper on NCT04513665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513665.